All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the ALL Hub spoke with Bijal Shah, Moffitt Cancer Center, Tampa, US. We asked, Is the anti-CD19 CAR-T brexu-cel (formerly KTE-X19) safe and effective in B-ALL?
Is the anti-CD19 CAR-T brexu-cel safe and effective in B-ALL?
Shah evaluates safety and efficacy data from the ZUMA-3 study, evaluating brexu-cel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). He focuses on contextualizing these results in comparison with previously approved regimens.
Coagulation FXIII-A expression patterns can predict outcomes in pediatric BCP-ALL
In a recent study by Bettina Kárai et al. the correlation of three FXIII-A expression patterns to different BCP-ALL clinical outcomes were investigated in pediatric...
Genetic markers in the prognosis of patients with ALL
Despite much research, the mutational landscape of patients with acute lymphoblastic leukemia (ALL) remains relatively poorly characterized, especially for rarer subtypes.
Subscribe to get the best content related to ALL delivered to your inbox